Giredestrant (Synonyms: GDC-9545) |
| Katalog-Nr.GC39630 |
Giredestrant (GDC-9545) ist ein nichtsteroidales Östrogenrezeptor(ER)-Ligand, der oral aktiv und selektiver ER-Antagonist ist. Giredestrant konkurriert effektiv mit Estradiol um die Bindung und induziert eine Konformationsänderung innerhalb des ER-Liganden-Bindungsdomäne. Giredestrant hat antitumorale Aktivität.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1953133-47-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity[1].
[1]. C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *